Asthma Management (GINA guidelines, SMART therapy)

Tuesday, February 10, 2026

🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.

1. As-needed ICS-formoterol vs SABA reliever for mild asthma exacerbation prevention

Global guideline evidence synthesis (2025) - Practice Guideline/Meta-analysis

Key Findings

Reliever-only SABA strategies were associated with higher exacerbation risk than anti-inflammatory reliever approaches.
As-needed low-dose ICS-formoterol reduced severe exacerbations with similar or lower cumulative steroid exposure.

📋 Practice Implication: For mild asthma, move away from SABA-only rescue; prefer ICS-containing reliever strategy.

2. Single Maintenance and Reliever Therapy (SMART) lowers severe exacerbations in persistent asthma

Multicenter pooled RCT update (2025) - Meta-analysis of RCTs

Key Findings

SMART reduced severe exacerbations versus fixed-dose ICS/LABA plus SABA rescue.
Benefits were consistent across adult and adolescent subgroups with moderate-to-severe disease.

📋 Practice Implication: Use budesonide-formoterol SMART as a default escalation option before adding oral steroid bursts.

3. Step-up timing: early controller intensification after flare reduces near-term relapse

Primary care pragmatic trial (2025) - Randomized Controlled Trial

Key Findings

Early post-exacerbation controller intensification reduced 90-day relapse visits.
Structured follow-up and inhaler technique checks improved adherence metrics.

📋 Practice Implication: Schedule early post-flare follow-up and step up controller therapy promptly.

4. GINA-aligned anti-inflammatory reliever pathways in real-world primary care

Health-system implementation study (2025) - Pragmatic RCT

Key Findings

Clinics adopting GINA-aligned pathways showed fewer urgent-care exacerbation encounters.
Protocolized reliever changes improved prescribing consistency.

📋 Practice Implication: Embed EHR order sets favoring ICS-formoterol reliever pathways in PCP workflows.

5. Oral corticosteroid stewardship bundle reduces cumulative steroid exposure

System-level intervention study (2025) - Pragmatic RCT

Key Findings

Stewardship bundle reduced total oral corticosteroid days without worsening exacerbation outcomes.
Decision-support nudges increased controller optimization before prednisone prescribing.

📋 Practice Implication: Adopt oral steroid stewardship prompts to reduce avoidable cumulative steroid harm.

Recent high-evidence asthma updates reinforce a major primary-care shift: avoid SABA-only rescue and prioritize anti-inflammatory reliever strategies, especially ICS-formoterol. SMART (single maintenance and reliever therapy) continues to show the strongest reduction in severe exacerbations versus traditional fixed-dose controller plus SABA rescue. Implementation-focused evidence also supports protocolized post-exacerbation follow-up and oral steroid stewardship to reduce relapse and cumulative corticosteroid harm.

Asthma Management (GINA guidelines, SMART therapy)

1. As-needed ICS-formoterol vs SABA reliever for mild asthma exacerbation prevention

2. Single Maintenance and Reliever Therapy (SMART) lowers severe exacerbations in persistent asthma

3. Step-up timing: early controller intensification after flare reduces near-term relapse

4. GINA-aligned anti-inflammatory reliever pathways in real-world primary care

5. Oral corticosteroid stewardship bundle reduces cumulative steroid exposure

💡 Summary